Viatris Inc (VTRS)

Industry Drug Manufacturers - Specialty & Generic

This stock can be held in an Investment ISA and an Investment Account

Sell

$11.55

Buy

$11.65

arrow-up$0.06 (+0.52%)

Prices updated at 13 Dec 2025, 00:36 EST

Prices minimum 15 mins delay

Prices in USD

Mylan NV is a generic pharmaceutical manufacturer which develops, licenses, manufactures, markets and distributes generic, over-the-counter (OTC) products in a variety of dosage forms and therapeutic categories.

NASDAQ

-1.69%

NASDAQ

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Chairman

Ms. Melina E. Higgins

CEO

Mr. Scott A. Smith

Most recent earnings

31 Dec 2024

Fiscal year end

31 Dec 2024

Employees

30,000

Head office

1000 Mylan Boulevard

Canonsburg

United States

15317

+1 724 514-1800

InvestorRelations@Viatris.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Mr. Harry A. Korman Independent Director	0.18m
Mr. Rajiv Malik Director	0.13m
Mr. David S. Simmons Independent Director	-
Dr. Michael Severino, M.D. Independent Director	-
Mr. Frank D’Amelio Independent Director	-
Ms. Elisha W. Finney Independent Director	0.15m
Mr. James M. Kilts Independent Director	0.15m
Mr. Wyllie Don Cornwell Independent Director	0.15m
Mr. Mark W. Parrish Vice Chairman of the Board	0.25m
Mr. Scott A. Smith Director and Chief Executive Officer	1.40m
Ms. Melina E. Higgins Chairman of the Board	0.43m
Ms. JoEllen Lyons Dillon Independent Director	0.20m
Dr. Rogerio Vivaldi Coelho, M.B.A.,M.D. Independent Director	0.09m
Mr. Paul B. Campbell Chief Accounting Officer and and Corporate Controller	0.72m
Mr. Richard A. Mark, C.P.A. Independent Director	0.20m
Dr. Corinne Le Goff, Pharm.D. Chief Commercial Officer	0.61m
Mr. Brian Roman Chief Legal Officer	0.82m
Mr. Leo Groothuis Independent Director	0.18m
Ms. Theodora Mistras Chief Financial Officer	0.81m
Mr. Andrew Enrietti Chief Administrative and Transformation Officer	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
Vanguard Group Inc	145,115,010
T. Rowe Price Associates, Inc.	84,064,766
BlackRock Inc	81,959,740
Davis Selected Advisers	69,345,645
Davis Selected Advisers LP	62,647,266

Director dealings

Date chevron-l-regular chevron-r-regular	Action
11 Nov 2024	-
12 Sep 2024	-
12 Sep 2024	-
30 Aug 2024	-
28 Aug 2024	-
22 Aug 2024	-
21 Aug 2024	-
23 Aug 2024	-
13 Jun 2024	-
14 Jun 2024	-
03 Jun 2024	-
28 May 2024	-
18 Apr 2024	-
18 Apr 2024	-
02 Apr 2024	-
13 Mar 2024	-
04 Mar 2024	-
04 Mar 2024	-
03 Mar 2024	-
03 Mar 2024	-

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.